

Siga

Ending depression

Siga is a neuroscience research catalyst with the goal of ending depression by turning science backed interventions into clinical practices.

Our approach: we invite research teams through open bids and active search to evidence innovative approaches that lead to the full remission of depression. Instead of creating a team ourselves, we leverage the expertise of researchers around the world in an open-access and competitive research environment.


The interventions need to have a clear value for clinicians or clients at any stage of a treatment. A few examples include algorithms that match symptoms with treatments, wearables that identify early symptoms, or innovative psychotherapies.

Why: 2 billion people worldwide have or have had depression in their lifetime. **Less than half** of people with depression in **developed** countries [receive treatment](#). And about [half](#) of those who undergo treatment do not fully [recover](#).

Depression is not simply sadness or lack of motivation, but a disabling clinical condition characterized by acute negative feelings that, among other things, increases the chances of suicide. The burdens of depression are felt by families, friends and society as depression and anxiety disorders cost **US\$ 1 trillion** [each year](#) in lost productivity worldwide.

Our model: We have the single goal of ending major depressive disorder. We work with teams around the world in a multistage approach that speeds discovery. We focus on practical solutions that can be quickly turned into effective products / services. We are backed by hard science and adhere to the most rigorous evidence protocols.

How it works (in a nutshell):



Contact:

João Lobato

<https://cooperandsacks.org/siga>

j.lobato@cooperandsacks.org + 258872650048

j.lobato.work@gmail.com